고중성지방혈증 환자에서 단기간의 Fenofibrate 투여가 혈중크레아티닌 농도에 미치는 영향
Effect of Short-term Fenofibrate Therapy on Blood Creatinine Levels in Patients with Hypertriglyceridemia
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Previous studies have reported that fenofibrate therapy increases blood creatinine levels. The aim of this studywas to evaluate the effect of fenofibrate therapy on the renal function in patients with hypertriglyceridemia and to determine theparameters associated with changes in renal functions. Methods: This prospective study enrolled 86 hypertriglyceridemic patients (triglycerides ≥ 200 mg/dL) who were divided into twogroups: the fenofibrate group (n = 43), who received 160 mg of fenofibrate, and the control group (n = 43). Lipid profiles and renalfunction were measured at the beginning of the study and after 2 months. Results: The estimated glomerular filtration rate (eGFR) decreased in the fenofibrate group (p < 0.001), but did not change in thecontrol group (p = 0.80). Accordingly, the decrease was more pronounced in the fenofibrate group than the control group (-18.6 ±8.6 vs. 0.9 ± 9.6%, respectively; p < 0.001). Changes in serum creatinine (p < 0.001) and blood urea nitrogen (p < 0.005) levels weresimilar to those of eGFR. In a stepwise linear regression analysis, the percent change in creatinine was independently associatedwith fenofibrate therapy (r = 0.71; p < 0.001) and old age (r = 0.27; p < 0.05) in all patients. In the fenofibrate group, percent changein creatinine was associated with age (r = -0.51; p < 0.001) and smoking (r = 0.42; p < 0.005), while percent change was associatedwith body mass index (r = 0.31; p < 0.05) in the control group. Elevation of creatinine by 20% or more was associated withfenofibrate therapy (p < 0.001) and old age (p < 0.005) in all patients, and with old age (p < 0.001) in the fenofibrate group. Conclusions: Short-term fenofibrate therapy significantly impaired the renal function of hypertriglyceridemic patients, and thiseffect was more pronounced in elderly patients. This finding suggests that creatinine levels should be followed in patients receivingfenofibrate therapy.
Abstract
Background/Aims: Previous studies have reported that fenofibrate therapy increases blood creatinine levels. The aim of this studywas to evaluate the effect of fenofibrate therapy on the renal function in patients with hypertriglyceridemia and to determine theparameters associated with changes in renal functions. Methods: This prospective study enrolled 86 hypertriglyceridemic patients (triglycerides ≥ 200 mg/dL) who were divided into twogroups: the fenofibrate group (n = 43), who received 160 mg of fenofibrate, and the control group (n = 43). Lipid profiles and renalfunction were measured at the beginning of the study and after 2 months. Results: The estimated glomerular filtration rate (eGFR) decreased in the fenofibrate group (p < 0.001), but did not change in thecontrol group (p = 0.80). Accordingly, the decrease was more pronounced in the fenofibrate group than the control group (-18.6 ±8.6 vs. 0.9 ± 9.6%, respectively; p < 0.001). Changes in serum creatinine (p < 0.001) and blood urea nitrogen (p < 0.005) levels weresimilar to those of eGFR. In a stepwise linear regression analysis, the percent change in creatinine was independently associatedwith fenofibrate therapy (r = 0.71; p < 0.001) and old age (r = 0.27; p < 0.05) in all patients. In the fenofibrate group, percent changein creatinine was associated with age (r = -0.51; p < 0.001) and smoking (r = 0.42; p < 0.005), while percent change was associatedwith body mass index (r = 0.31; p < 0.05) in the control group. Elevation of creatinine by 20% or more was associated withfenofibrate therapy (p < 0.001) and old age (p < 0.005) in all patients, and with old age (p < 0.001) in the fenofibrate group. Conclusions: Short-term fenofibrate therapy significantly impaired the renal function of hypertriglyceridemic patients, and thiseffect was more pronounced in elderly patients. This finding suggests that creatinine levels should be followed in patients receivingfenofibrate therapy.
참고문헌 (24)
- Abourbih S, "Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review", Am J Med, 122, pp.962.e1~962.e8 (2009)
- Shah A, "The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans", Atherosclerosis, 210, pp.35~40 (2010)
- Davidson MH, "Safety considerations with fibrate therapy", Am J Cardiol, 99(6A), pp.3C~18C (2007)
- Lageder H, "Comparative double-blind investigation of bezafibrate and clofibrate in patients with primary hyperlipoproteinaemia", Wien Klin Wochenschr, 92, pp.95~101 (1980)
- Dick TB, "Comparative study of once and 3-times daily regimens of bezafibrate in patients with primary hyperlipoproteinaemia", Curr Med Res Opin, 7, pp.489~502 (1981)
- Rossner S, "Fenofibrate therapy of hyperlipoproteinaemia. A dose-response study and a comparison with clofibrate", Atherosclerosis, 38, pp.273~282 (1981)
- Hokanson JE, "Plasma triglyceride level is a risk factor for cardiovascular disease independent of highdensity lipoprotein cholesterol level: a meta-analysis of population-based prospective studies", J Cardiovasc Risk, 3, pp.213~219 (1996)
- Kim MA, "Triglyceride and cardiovascular disease", J Lipid Atheroscler, 2, pp.1~8 (2013)
- Sarwar N, "Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies", Circulation, 115, pp.450~458 (2007)
- The Emerging Risk Factors Collaboration, "Major lipids, apolipoproteins, and risk of vascular disease", JAMA, 302, pp.1993~2000 (2009)
- Diabetes Atherosclerosis Intervention Study Investigators, "Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study", Lancet, 357, pp.905~910 (2001)
- Keech A, "FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial", Lancet, 366, pp.1849~1861 (2005)
- The ACCORD Study Group, "Effects of combination lipid therapy in type 2 diabetes mellitus", N Engl J Med, 362, pp.1563~1574 (2010)
- Hottelart C, "Fenofibrate increases creatininemia by increasing metabolic production of creatinine", Nephron, 92, pp.536~541 (2002)
- Ritter JL, "Fenofibrate-induced elevation in serum creatinine", Pharmacotherapy, 21, pp.1145~1149 (2001)
- Deighan CJ, "Comparative effects of cerivastatin and fenofibrate on the atherogenic lipoprotein phenotype in proteinuric renal disease", J Am Soc Nephrol, 12, pp.341~348 (2001)
- Broeders N, "Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent", Nephrol Dial Transplant, 15, pp.1993~1999 (2000)
- Ansquer JC, "Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people", Am J Kidney Dis, 51, pp.904~913 (2008)
- Cho JH, "Effect of fenofibrate therapy on blood creatinine levels in patients with hypertension and hypertriglyceridemia", J Lipid Atheroscler, 2, pp.19~26 (2013)
- Davis TM, "Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study", Diabetologia, 54, pp.280~290 (2011)
- Williams AJ, "The short term effects of bezafibrate on the hypertriglyceridaemia of moderate to severe uraemia", Br J Clin Pharmacol, 18, pp.361~367 (1984)
- Hottelart C, "Fenofibrate increases creatininemia by increasing metabolic production of creatinine", Nephron, 92, pp.536~541 (2002)
- Angeles C, "Fenofibrateassociated reversible acute allograft dysfunction in 3 renal transplant recipients:biopsy evidence of tubular toxicity", Am J Kidney Dis, 44, pp.543~550 (2004)
- Dierkes J, "Serum homocysteine increases after therapy with fenofibrate or bezafibrate", Lancet, 354, pp.219~220 (1999)